exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087592 RNA Name: hsa-let-7g-5p RNA Type: miRNA Chromosome: chr3 Starnd: - Coordinate: Start Site(bp): 52268336 End Site(bp): 52268357 External Links: hsa-let-7g-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ACP1 chr2 264140 278283 + ARID3B chr15 74541177 74598131 + BACH1 chr21 29194071 29630751 + BLOC1S6 chr15 45587214 45615945 + C15orf41 chr15 36579626 36810248 + COIL chr17 56938199 56961050 - CREM chr10 35126791 35212958 + CTPS2 chrX 16587999 16712936 - GRPEL2 chr5 149345430 149354583 + HDLBP chr2 241227264 241317061 - HMGA2 chr12 65824131 65966295 + IGDCC3 chr15 65327127 65378002 - IGF2BP1 chr17 48997385 49056145 + INTS6L chrX 135520643 135582510 + LIMD1 chr3 45555394 45686341 + LRIG3 chr12 58872149 58920522 - MARCKSL1 chr1 32333839 32336233 - PDPR chr16 70113626 70162537 + PHC3 chr3 170086732 170181749 - PLD3 chr19 40348456 40380439 + RANBP2 chr2 108719482 108785809 + RTKN chr2 74425835 74442422 - STRBP chr9 123109500 123268586 - TNRC6B chr22 40044817 40335808 + TRIM65 chr17 75880335 75896951 - UBE2G2 chr21 44768580 44801826 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000247 chr10 74474868 74475660 + hsa_circ_0000987 chr2 30748452 30756180 + hsa_circ_0000246 chr10 74468040 74475660 + hsa_circ_0000018 chr1 15860731 15863309 + hsa_circ_0000038 chr1 28800065 28802803 + hsa_circ_0000799 chr17 65941524 65972074 + hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC006064.5 chr12 6510275 6510522 + AC074117.1 chr2 27356246 27367622 + AC109460.3 chr16 28974804 28990775 + AC124045.1 chr3 44667412 44669364 + AP000766.1 chr11 107312132 107316271 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - KCNQ1OT1 chr11 2608328 2699994 - LINC00265 chr7 39733430 39793092 + LINC02381 chr12 54126082 54147485 + MIRLET7BHG chr22 46053869 46113928 + NEAT1 chr11 65422774 65445540 + NUTM2A-AS1 chr10 87201647 87342612 - SNHG16 chr17 76557764 76565348 + SNHG4 chr5 139274102 139284899 + TMPO-AS1 chr12 98512973 98516422 - XIST chrX 73820649 73852723 - ZNF436-AS1 chr1 23368997 23371839 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.